Claim OwnershipThe Long Run with Luke Timmerman
Subscribed: 343Played: 10,664
Subscribe
© All rights reserved
Description
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
154 Episodes
Reverse
David Liu, professor of chemistry at Harvard University and co-founder of multiple biotech companies, including Beam Therapeutics and Prime Medicine.
Valerie Daggett, founder and CEO of Seattle-based AltPep, on early detection and treatment of Alzheimer's.
Robert Ang, CEO of Cambridge, Mass.-based Vor Bio, on using CRISPR gene editing to alter bone marrow transplants and improve treatment of acute myeloid leukemia.
Rick Young, professor at MIT and co-founder of Syros Pharmaceuticals, CAMP4 Therapeutics, Omega Therapeutics, and Dewpoint Therapeutics, on studying gene expression for drug discovery.
Jens Eckstein, investment partner at Hevolution Foundation, on investing in healthy aging.
Shelley Force Aldred and Nathan Trinklein, co-founders of Rondo Therapeutics, on the opportunity with bispecific antibodies for cancer.
Jeff Jonker, CEO of San Diego-based Belharra Therapeutics, on the renaissance in small molecule drug discovery.
Nancy Stagliano, CEO of South San Francisco-based Neuron23, on bringing precision medicine to neuroscience drug discovery.
Diana Brainard, CEO of AlloVir, on leading the fight against infectious diseases.
Reid Huber, partner at Third Rock Ventures, on investing in the future of medicine.
Jeff Huber, co-founder and general partner at Triatomic Capital, on his career path in tech, and then biotech.
Lori Lyons-Williams, CEO of Abdera Therapeutics, on developing targeted radiopharmaceuticals for cancer.
Turning the Tables, Rob Perez Interviews Me
Zach Weinberg and Alexis Borisy of Curie.Bio on Freeing the Biotech Founders
Fred Appelbaum, a physician, scientist and leader at the Fred Hutchinson Cancer Center, on 'Living Medicine,' his new book about the development of bone marrow transplantation and the rise of cell therapy.
Colin Hill, co-founder and CEO of Aitia, on digging deep into biological datasets and finding new drug targets.
Yung Lie, president and CEO of Damon Runyon Cancer Research Foundation, on advancing cancer research by supporting young scientists with bold and brave ideas.
1Kevin Conroy, CEO of Exact Sciences, on early detection of cancer.
Jodie Morrison, acting CEO of Q32Bio, on becoming a biotech CEO.
Aaron Ring, a scientist at Yale moving to the Fred Hutchinson Cancer Center, on applying immunology and protein engineering for cancer therapy and more.
Comments
Download from Google Play
Download from App Store
United States